These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1275 related articles for article (PubMed ID: 30426665)

  • 1. Real-world efficacy and toxicity of combined nivolumab and ipilimumab in patients with metastatic melanoma.
    Parakh S; Randhawa M; Nguyen B; Warburton L; Hussain MA; Cebon J; Millward M; Yip D; Ali S
    Asia Pac J Clin Oncol; 2019 Feb; 15(1):26-30. PubMed ID: 30426665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of ipilimumab after anti-PD-1 therapy in sequential treatment of metastatic melanoma patients - Real world evidence.
    Cybulska-Stopa B; Rogala P; Czarnecka AM; Ługowska I; Teterycz P; Galus Ł; Rajczykowski M; Dawidowska A; Piejko K; Suwiński R; Mackiewicz J; Rutkowski P
    Adv Med Sci; 2020 Sep; 65(2):316-323. PubMed ID: 32554313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.
    Long GV; Atkinson V; Lo S; Sandhu S; Guminski AD; Brown MP; Wilmott JS; Edwards J; Gonzalez M; Scolyer RA; Menzies AM; McArthur GA
    Lancet Oncol; 2018 May; 19(5):672-681. PubMed ID: 29602646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term Overall Survival and Predictors in Anti-PD-1-naive Melanoma Patients With Brain Metastases Treated With Immune Checkpoint Inhibitors in the Real-world Setting: A Multicohort Study.
    Naik GS; Buchbinder EI; Cohen JV; Manos MP; Johnson AEW; Bowling P; Aizer AA; Schoenfeld JD; Lawrence DP; Haq R; Hodi FS; Sullivan RJ; Ott PA
    J Immunother; 2021 Oct; 44(8):307-318. PubMed ID: 34406158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study.
    Namikawa K; Kiyohara Y; Takenouchi T; Uhara H; Uchi H; Yoshikawa S; Takatsuka S; Koga H; Wada N; Minami H; Hatsumichi M; Asada S; Namba Y; Yamazaki N
    Eur J Cancer; 2018 Dec; 105():114-126. PubMed ID: 30447539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases.
    Parakh S; Park JJ; Mendis S; Rai R; Xu W; Lo S; Drummond M; Rowe C; Wong A; McArthur G; Haydon A; Andrews MC; Cebon J; Guminski A; Kefford RF; Long GV; Menzies AM; Klein O; Carlino MS
    Br J Cancer; 2017 Jun; 116(12):1558-1563. PubMed ID: 28524161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity.
    Minniti G; Anzellini D; Reverberi C; Cappellini GCA; Marchetti L; Bianciardi F; Bozzao A; Osti M; Gentile PC; Esposito V
    J Immunother Cancer; 2019 Apr; 7(1):102. PubMed ID: 30975225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Japanese real-world study of sequential nivolumab and ipilimumab treament in melanoma.
    Tsutsumida A; Fukushima S; Yokota K; Yoshikawa S; Yamasaki O; Tanemura A; Okuyama R; Uhara H; Muto Y; Miyashita A; Akiyama M; Kaji T; Koga H; Kato J; Katayama T; Itakura E; Yamazaki N; Kiyohara Y
    J Dermatol; 2019 Nov; 46(11):947-955. PubMed ID: 31531895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.
    Weber JS; Gibney G; Sullivan RJ; Sosman JA; Slingluff CL; Lawrence DP; Logan TF; Schuchter LM; Nair S; Fecher L; Buchbinder EI; Berghorn E; Ruisi M; Kong G; Jiang J; Horak C; Hodi FS
    Lancet Oncol; 2016 Jul; 17(7):943-955. PubMed ID: 27269740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of BRAF mutation status on clinical outcomes with anti-PD-1 monotherapy versus combination ipilimumab/nivolumab in treatment-naïve advanced stage melanoma.
    Ma VT; Daignault-Newton S; Waninger JJ; Journey S; Chopra Z; Tezel A; Redman BG; Fecher LA; Green MD; Alva AS; Lao CD
    Pigment Cell Melanoma Res; 2021 May; 34(3):629-640. PubMed ID: 33128316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study.
    Serra-Bellver P; Versluis JM; Oberoi HK; Zhou C; Slattery TD; Khan Y; Patrinely JR; Pires da Silva I; Martínez-Vila C; Cook N; Graham DM; Carlino MS; Menzies AM; Arance AM; Johnson DB; Long GV; Pickering L; Larkin JMG; Blank CU; Lorigan P
    Eur J Cancer; 2022 Nov; 176():121-132. PubMed ID: 36215945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.
    Pires da Silva I; Ahmed T; Reijers ILM; Weppler AM; Betof Warner A; Patrinely JR; Serra-Bellver P; Allayous C; Mangana J; Nguyen K; Zimmer L; Trojaniello C; Stout D; Lyle M; Klein O; Gerard CL; Michielin O; Haydon A; Ascierto PA; Carlino MS; Lebbe C; Lorigan P; Johnson DB; Sandhu S; Lo SN; Blank CU; Menzies AM; Long GV
    Lancet Oncol; 2021 Jun; 22(6):836-847. PubMed ID: 33989557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with front-line BRAF/MEK inhibitors, anti-PD-1 antibodies, or nivolumab/ipilimumab.
    Moser JC; Chen D; Hu-Lieskovan S; Grossmann KF; Patel S; Colonna SV; Ying J; Hyngstrom JR
    Cancer Med; 2019 Dec; 8(18):7637-7643. PubMed ID: 31677253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study.
    Najjar YG; Navrazhina K; Ding F; Bhatia R; Tsai K; Abbate K; Durden B; Eroglu Z; Bhatia S; Park S; Chowdhary A; Chandra S; Kennedy J; Puzanov I; Ernstoff M; Vachhani P; Drabick J; Singh A; Xu T; Yang J; Carvajal R; Manson D; Kirkwood JM; Cohen J; Sullivan R; Johnson D; Funchain P; Shoushtari A
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.
    Hodi FS; Chesney J; Pavlick AC; Robert C; Grossmann KF; McDermott DF; Linette GP; Meyer N; Giguere JK; Agarwala SS; Shaheen M; Ernstoff MS; Minor DR; Salama AK; Taylor MH; Ott PA; Horak C; Gagnier P; Jiang J; Wolchok JD; Postow MA
    Lancet Oncol; 2016 Nov; 17(11):1558-1568. PubMed ID: 27622997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
    Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
    JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study.
    Tawbi HA; Forsyth PA; Hodi FS; Algazi AP; Hamid O; Lao CD; Moschos SJ; Atkins MB; Lewis K; Postow MA; Thomas RP; Glaspy J; Jang S; Khushalani NI; Pavlick AC; Ernstoff MS; Reardon DA; Kudchadkar R; Tarhini A; Chung C; Ritchings C; Durani P; Askelson M; Puzanov I; Margolin KA
    Lancet Oncol; 2021 Dec; 22(12):1692-1704. PubMed ID: 34774225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma.
    Rosner S; Kwong E; Shoushtari AN; Friedman CF; Betof AS; Brady MS; Coit DG; Callahan MK; Wolchok JD; Chapman PB; Panageas KS; Postow MA
    Cancer Med; 2018 Mar; 7(3):690-697. PubMed ID: 29468834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
    Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
    JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose ipilimumab combined with anti-PD-1 immunotherapy in patients with metastatic melanoma following anti-PD-1 treatment failure.
    Klee G; Kurzhals J; Hagelstein V; Zillikens D; Recke A; Langan EA; Terheyden P
    Melanoma Res; 2021 Oct; 31(5):464-471. PubMed ID: 34284462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 64.